Sapiens International Corporation SPNS shares have returned 18.8% year to date, outperforming the Zacks Computer Software industry’s gain of 16.9%. The insuretech provider benefits from a robust portfolio, expanding clientele and strong partner base. SPNS recently announced the launch of its cutting-edge AI-powered, cloud-native insurance platform. The Sapiens Insurance Platform is designed to leverage digital engagement, data intelligence, core business processing solutions, and advanced machine learning and generative AI (GenAI) capabilities to help insurers innovate and stay competitive in today’s dynamic market. In a move to strengthen its footprint in the Medical Professional Liability (MPL) domain, SPNS recently announced a strategic investment in Sapiens CoreSuite for MPL. This initiative aims to drive growth and innovation within the MPL industry by enhancing capabilities in policy administration, finance, claims, and risk management. SPNS’ advanced, integrated solution is designed to manage the complexities of MPL operations and adapt swiftly to new regulatory requirements and industry standards. Enhanced functionality, flexibility and superior user experiences are key features of Sapiens CoreSuite for MPL, offering substantial new business value. SPNS YTD Performance Zacks Investment Research Image Source: Zacks Investment Research Sapiens CoreSuite for MPL stands out as the only solution tailored specifically for the complex needs of the MPL market. It provides an end-to-end, core insurance solution that supports individuals, groups, hospitals and institutional businesses through the entire policy lifecycle, from policy quoting to claim resolution. Expanding Partner Base, International Footprint Aids Prospect Sapiens is riding on growing clientele, as well as a strong partner base. An expanding partner base that includes the likes of Microsoft MSFT, DataCrest, Binah.ai, Deloitte, PWC and LTIMindtree has been a key catalyst. Sapiens’ partnership with Microsoft has been a game changer. SPNS is one of the few selected vendors collaborating with MSFT on OpenAI. SPNS recently launched IntegrateAI, the newest capability from Sapiens Decision, integrating machine learning models into the business-friendly decision model workbench. IntegrateAI follows Sapiens Decision's recent ModelAI release, which brings a Generative AI copilot to decision modelers with integration to Microsoft Azure’s OpenAI Service. SPNS’ expanding international footprint in the U.K., Germany, the Caribbean, Thailand and Canada is noteworthy. Sapiens recently announced that Bangkok Insurance Public Company Limited (BKI), a leading insurer in Thailand, has successfully implemented the Sapiens Property & Casualty (P&C) platform. This implementation, which includes the Sapiens IDITSuite for Property & Casualty, Sapiens ReinsuranceMaster and Sapiens Intelligence, marks one of the most extensive and complex projects in the Thai insurance sector to date. Republic Life, a Caribbean-based company, adopted Sapiens CoreSuite for Life & Annuities and Sapiens Digital Suite hosted on Microsoft Azure cloud. Sapiens expanded its footprint into Canada on the back of its Saskatchewan Workers’ Compensation Board partnership. Meanwhile, BHSF, a U.K. “profit for good” health and wellbeing provider, has chosen to deploy the Sapiens Platform, including Sapiens IDITSuite for P&C and Sapiens DigitalSuite. German pet insurance brand Cleo also deployed Sapiens SCIPSuite to accelerate its underwriting, digital sales and go-to-market processes. Sapiens’ Outlook Remains Positive For 2024, the company still expects revenues between $550 million and $555 million. The Zacks Consensus Estimate for 2024 revenues is pegged at $553.45 million, indicating year-over-year growth of 7.55%. Operating income is expected between $99.6 million and $102.7 million. SPNS still expects a non-GAAP operating margin between 18.1% and 18.5%. The consensus mark for earnings is pegged at $1.48 per share, unchanged over the past 60 days, indicating 9.63% over 2023. Zacks Rank & Other Stocks to Consider Sapiens currently sports a Zacks Rank #1 (Strong Buy). NVIDIA NVDA and Amphenol APH are a couple of other top-ranked stocks in the broader Zacks Computer & Technology sector, each currently sporting a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here. Long term earnings growth rate for NVIDIA and Amphenol is currently pegged at 37.57% and 12.69%, respectively. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Microsoft Corporation (MSFT):Free Stock Analysis Report Amphenol Corporation (APH):Free Stock Analysis Report NVIDIA Corporation (NVDA):Free Stock Analysis Report Sapiens International Corporation N.V. (SPNS):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Sapiens (SPNS) Benefits From a Strong Portfolio, Partner Base
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...